Athenahealth’s Shares Up As Software Wins Physicians’ Approval
The Watertown, Massachusetts based company is one of the largest to make online health-record and medical-practice billing software and has a growing following amongst physicians; it’s network of doctors has ballooned by 28 percent. As a result of the its expanding network, the company’s shares shot up 14 percent in extended trading on Thursday, per Reuters.
Athenahealth‘s products include its billing product, athenaCollector, its practice-management software, athenaClinicals, as well as its athenaCommunicator software which streamlines physician and patient communication. Athenahealth also bought the mobile medical application business known as Epocrates in March which contributed 18.9 million to the company’s revenue.
Athenahleath has reported that its net income rose to $13.1 million, or 34 cents a share, from $5.9 million, or 16 cents a share in the fourth-quarter; Athenahealth’s revenue surged 48 percent to $171.6 million. Analysts were expecting a net income of approximately 44 cents a share on $168.4 million in revenue.
The company’s earnings-per-share growth was “positively impacted by very strong gross margin performance as well as better-than-expected Epocrates contribution” ISI Group analyst Michael Cherney wrote, per Reuters.
Another analyst Ryan Daniels of William Blair & Co. said Athenahealth’s fourth-quarter was “a reversal from the last several quarters where both sales and earnings were modestly shy of expectations.” Daniels rated the stock “market perform” saying that growth for the athenaCollector and athenaClinicals programs was better than expected, per NBC.
Shares of Athenahealth have been trading at all-time highs for almost a year now; shares closed at $139.08 on Nasdaq Thursday and peaked at $177.79 on Friday. As of Friday the stock is up almost 70 percent since the company reported its third quarter results in October.
More From Wall Street Cheat Sheet:
- Investor Seeks Board Seats at Ariad Pharmaceuticals
- Furiex Pharmaceuticals Doubles, But Stock Is Now Fairly Priced
- Is Johnson & Johnson a Rare Big Pharma Opportunity?